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Abstract We have previously shown that direct binding of the 
Py subunit of G protein (GPY) to both the N-terminal domain and 
the C-terminal domain of a cloned G protein-gated inward-
rectifying K+ channel subunit, GIRK1, is important for channel 
activation. We have now further localized the GPY binding region 
in the N-terminal domain of GIRK1 to amino acids 34-86 and 
the GPy binding region in the C-terminal domain of GIRK1 to 
two separate fragments of amino acids 318-374 and amino acids 
390-462. Of the four cloned mammalian GIRK subunits, 
GIRKl^l, GIRK1 and 4 form heteromeric K+ channels in the 
heart and similar channels in the brain include heteromultimers 
of GIRK1 and 2, and possibly other GIRK homomultimers and 
heteromultimers. We found that the N-terminal and the C-
terminal domains of all four GIRKs bound GPy. The Gpy binding 
activities for the C-terminal domains of GIRK2^I were lower 
than that for the C-terminal domain of GIRK1. The higher GPy 
binding activity for the C-terminal domain of GIRK1 is due to 
amino acids 390-462 which are unique to GIRK1. We also found 
that the N-terminal and C-terminal domains of GIRKs 
interacted with each other, and the N-terminal domain of either 
GIRK1 or GIRK4 together with the C-terminal domain of 
GIRK1 exhibited much enhanced binding of GPy. These results 
are consistent with the idea that the N- and C-terminal domains 
of the cardiac G protein-gated K+ channel subunits may 
interact with each other to form higher affinity binding site(s) 
for Gpy. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Activation of G protein-gated inwardly rectifying K+ chan-
nel by G protein-coupled receptors represents one mechanism 
of inhibitory synaptic transmission [1]. In the heart, activation 
of the muscarinic K+ channel by acetylcholine results in slow-
ing of the heart rate [2-A]. In the nervous system, activation 
of similar G protein-activated K+ channels may mediate 
the inhibitory action of neurotransmitters such as somatosta-
tin, adenosine, serotonin, opioid peptides and y-aminobutyric 
acid (GABAB) [1,5,6]. The Py subunit of G protein (GPY) 
activates these K+ channels via a membrane-delimited path-
way that does not involve water-soluble cytoplasmic factors 
[7-9]. 
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The cDNAs for G protein-gated inward-rectifying K+ 
channel subunits, GIRK1-5, which share ~ 6 0 % identity in 
amino acid sequence, have recently been isolated [10-14]. 
GIRK5 is cloned from Xenopus and no mammalian homologs 
of GIRK5 have been reported. While GIRK2 appears to form 
homomeric K+ channels in oocyte and probably in dopamine 
neurons in the midbrain [15-19], G protein-activated K+ 
channel in many tissues are likely heteromultimers of different 
subunits of the isoforms. The atrial muscarinic K+ channel is 
a heteromultimer of GIRK1 and GIRK4 [13,20-22]. Neuro-
nal G protein-activated K+ channels include heteromultimers 
of GIRK1 and GIRK2 [15,19,20,23]. Indeed, a point muta-
tion of the GIRK2 gene is associated with weaver mutation 
which causes loss of midbrain dopamine neurons as well as 
cerebellar neurons [24]. Heteromultimers of GIRK2 and 4 
may also be functional K+ channels [15,20]. The role of 
GIRK3 in the formation of the G protein-gated K+ channels, 
however, is less clear. While several studies reveal no func-
tional activity of homomultimers of GIRK3 or heteromultim-
ers of GIRK3 and other GIRK subunits [12,15,20], other 
investigations reported functional expression of heteromultim-
ers of GIRK1 and GIRK3 [16] and heteromultimers of 
GIRK3 and GIRK4 [21] and inhibition of GIRK2 channel 
activity by GIRK3 [16]. One possibility raised as a plausible 
explanation for this variability is that GIRK3 does not con-
tain GPy binding sites and the activity of the heteromultimer 
depends upon the stoichiometry of GIRK3 in the heteromul-
timers [16]. 
To understand the mechanism for channel activation by 
GPy, it would be important to first identify regions of 
GIRK channel subunits that interact with GPy. Previously, 
we and others reported direct binding of Gpy to both the 
N- and C-terminal domains of GIRK1 [25-27] and that bind-
ing of GPy to both domains of GIRK1 is physiologically 
important for channel activation [25,27-31]. Direct binding 
of GPy to GIRK4 has also been reported [32]. Whether 
GIRK2 and 3 also bind GPy, however, is not known. In the 
present study, we show that GPy binds to both the N- and C-
terminal domains of GIRK2, GIRK3 and GIRK4. The GPy 
binding regions of GIRK1 have been further localized to ami-
no acids (A.A.) 34-86 in the N-terminal domain, and A.A. 
318-374 and A.A. 390^62 in the C-terminal domain of 
GIRK1. The amino acid sequences of the first two GPy bind-
ing regions of GIRK1 (34-86 and 318-374) are highly 
conserved among GIRK1-GIRK4. Furthermore, we found 
that the N-terminal domains of GIRK1 and GIRK4 inter-
act with the C-terminal domain of GIRK1, and these inter-
actions potentiate the binding of GPy to the channel frag-
ments. 
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2. Materials and methods 
2.1. Materials 
IPTG and molecular biological reagents were from Boehringer 
Mannheim. Glutathione 4B Sepharose beads, reduced glutathione 
and pGEX-2T vector were from Pharmacia. Iminodiacetic acid 
coupled-Sepharose beads charged with nickel ion were from Invitro-
gen. Donkey anti-rabbit IgG coupled with horseradish peroxidase 
and enhanced chemiluminescence (ECL) system for western blotting 
were from Amersham. Other chemicals including imidazole were 
from Sigma. E. coli DE 3 strain was used for fusion protein expres-
sion. 
2.2. Construction of plasmid and expression of GST fusion protein 
PGEX-2T vector was used for expression of recombinant bacterial 
fusion proteins. Nucleotide sequences corresponding to the peptide 
fragment of GIRK K+ channel subunits of interest were amplified 
by polymerase chain reaction (PCR) using forward primer containing 
an in-frame BamHI site immediately preceding the coding sequence of 
interest and reverse primer containing an EcoRl site following the 
coding sequence of interest. PCR products were subcloned into Bam-
HI and EcoKl sites of the pGEX-2T vector and confirmed by nucleo-
tide sequencing. The in-frame start and stop codons within the 
pGEX-2T vector were used for protein translation. Expression of 
fusion proteins was induced by 0.4 mM IPTG at 37°C for \-4 h as 
previously described [25]. Purification of GST fusion proteins contain-
ing GIRK fragments involve binding of the fusion proteins to gluta-
thione 4B Sepharose beads and eluting with 10 mM reduced gluta-
thione according to the Pharmacia product instruction manual as 
previously described [25,33]. Fusion proteins were dialyzed in phos-
phate-buffered saline (PBS) at 4°C and stored at -70°C. The purity 
and integrity of fusion proteins were checked by SDS-PAGE and 
Coomassie Blue staining. The concentration of fusion protein is de-
termined using a Bio-Rad protein assay kit (Bradford). 
2.3. Coprecipitation assay and western blotting 
For binding of Gpy to GST fusion proteins, purified bovine brain 
GPy (40 nM) [34] was incubated with GST fusion proteins at the 
indicated concentrations and 20 ul of glutathione Sepharose beads 
(suspended in an equal volume of PBS) in 50-100 ul of PBS contain-
ing 0.1% of the detergent Lubrol PX at 4°C for 30 min. Sepharose 
beads were spun down using a table-top micro-centrifuge and washed 
by resuspending beads in PBS followed by centrifugation. The wash 
with PBS was repeated 3 times. After the final wash, the Sepharose 
beads and precipitated proteins were resuspended in 20 |il of SDS-gel 
sample buffer and heated to 70°C for 10 min. Samples (10 u.1) were 
separated by 10% SDS-PAGE and transferred to nitrocellulose mem-
branes for western blotting and probing with specific antibodies and 
detection by ECL. Nitrocellulose filter containing precipitated pro-
teins was stained with Ponceau S to verify that the appropriate 
amount of each fusion protein was precipitated by affinity beads in 
each experiment. The production and characterization of the polyclo-
nal antibodies against GIRKl, GIRK4 and Gp have been described 
previously [19,25,35]. 
For binding of Gpy to H6-tagged fusion protein of GIRKs, Gpy (40 
nM) was incubated with GST-GKC-H6 at the indicated concentra-
tions and 20 ul of iminodiacetyl-coupled Sepharose beads charged 
with nickel (nickel affinity beads). Imidazole, a competitive antagonist 
for binding to the nickel beads, was included in the reaction to pre-
vent non-specific binding of proteins to the beads. 
For binding of the N-terminal fusion protein to the C-terminal 
fusion protein, GST-GKN or GST-G4N (1 uM) was incubated with 
GST-GKC-H6 (200 nM) and 20 ul of nickel affinity beads in the 
presence of imidazole (50 mM). The apparent half-binding constant 
(Kl/2) for binding of GKN or G4N to GST-GKC-H6 was estimated 
to be ~ 10-6 M according the following equation, ^1y2=[GST-
GKN]free/[GST-GKN-GST-GKC-H6]bound X [GST-GKC-H6]frHJ. The 
ratio of [GST-GKN]free to [GST-GKN-GST-GKC-H6]bomld was de-
termined from the immunoreactivity of GST-GKN in the supernatant 
vs. that of GST-GKN in the pellet containing the nickel affinity beads 
and precipitated proteins. When 1 (iM GST-GKN was incubated 
with 200 nM GST-GKC-H6 and co-precipitated with nickel affinity 
beads, we found that the ratio of the immunoreactivity of GST-GKN 
in the supernatant to that in the pellet was ~ 10:1. Ki/2 is, therefore, 
equal to 1.1 uM (910 nM [10/11 X1000] of GST-GKNfree divided by 
90 nM [1/11X1000] of GST-GKN-GST-GKC-H6bolmd and multiplied 
by 110 nM [200-90] of GST-GKC-H6free). 
3. Results 
3.1. Gpy binding site in the C-terminal domain of GIRKl 
Using the coprecipitation assay to detect interaction be-
tween purified GPy and hexahistidine (H6) tagged fusion pro-
teins containing the fragment of GIRKl, we have previously 
shown that GPy binds to the C-terminal domain of GIRKl 
[25]. Using glutathione-S-transferase (GST) fusion protein of 
GIRKl, Inanobe et al. [26] and Kunkel and Peralta [27] have 
also demonstrated binding of G(3y to the C-terminal domain 
of GIRKl. Previously, we localized the GPy binding site on 
the C-terminal domain of GIRKl to the region of A.A. 273-
462. To define further the GPy binding region in the C-termi-
nal domain of GIRKl, we made additional fusion proteins 
containing smaller fragments of GIRKl and examined copre-
cipitation of these proteins with the purified Gpy. 
In analyzing a series of deletion constructs, we found that 
deletion of A.A. 273-317 (as in GST-GKC318-462) did not 
affect binding of the fusion protein to GPy (Fig. 1). Further 
deletion of A.A. 318-339 (as in GST-GKC340-462), however, 
reduced the GPy binding activity of the fusion protein, indi-
cating that A.A. 318-339 either was part of the binding site or 
was important for the stability of the fusion protein. A fusion 
protein containing A.A. 180-374 (GST-GKC180-374) showed 
reduced GPy binding activity. Amino acids from 374—384 of 
GIRKl have been suggested to be important for binding with 
GPy based on its limited sequence homology with adenylate 
cyclase 2 [36]. We therefore made a GST fusion protein of the 
C-terminal domain of GIRKl with an internal deletion of 
A.A. 375-389 (GST-GKCi80-374; 390-462 with the fragment 
of amino acids 180-374 fused to the fragment of amino acids 
390^162) and found that the binding of GPy to this fusion 
protein was comparable to that of Gpy to GST-GKCigo-462, 
indicating that A.A. 375-389 is not critical for the GPy inter-
action. Taken together, these results indicate that the regions 
of A.A. 318-374 and A.A. 390-462 of the C-terminal domain 
of GIRKl are important for GPy binding. A smaller fusion 
protein containing A.A. 390^162 (GST-GKC39o_462), how-
ever, did not show detectable Gpy binding activity (not 
shown). We do not know whether this fusion protein is folded 
properly. Previously, we have shown that a peptide derived 
from amino acids 434-462 of GIRKl (peptide GC) [25] par-
tially inhibited binding of GPy to the entire C-terminal do-
main of GIRKl. We found that peptide GC partially inhib-
ited the binding of Gpy to GST-GKC340-462, but not that of 
GPy to GST-GKCi80-374 (Fig. 1C). This partial inhibition 
could be an indication that other amino acids besides 434-
462 in the region of amino acids 390^-62 are also important 
for GPy binding. 
3.2. Gpy binding activity of GIRK2-4 
The Hill coefficient for Gpy activation of atrial muscarinic 
K+ channel is > 1, indicating that more than one GPy is 
required for full activation of the G protein-gated K+ chan-
nels [37]. Since the atrial and neuronal G protein-gated in-
ward-rectifying K+ channels may include heteromultimers of 
GIRKl and 4 and heteromultimers of GIRKl and 2, respec-
tively, it would be important to determine whether GIRK2 
and 4 also bind Gpy. The findings that GPy can activate the 
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Fig. 1. Gpy binding region in the C-terminal domain of GIRKl. (A) Schematic diagram of GST fusion protein constructs of the C-terminal 
domain of GIRKl and Gpy binding activities for these constructs. (+) Indicates maximal binding activity; (J,) denotes reduced binding activity. 
(B) Localization of GPy binding region. GST fusion proteins containing fragments of the C-terminal domain of GIRKl or the control GST-
Kyi.2C or GST alone (200 nM) were incubated with purified bovine brain GPy (40 nM) and processed for coprecipitation by glutathione-Se-
pharose beads. Filter was probed with antibodies against Gp. The immunoreactivity for GP is indicated by the arrow. Similar results were ob-
served in 3 other experiments. (C) Partial inhibition of the binding of GPy to GST-GKC340-462 but not the binding to GST-GKCi80_374 by pep-
tide GC. Binding of Gpy to GST-GKC340-462 or GST-GKC180-374 was examined in the presence or absence of 100 uM peptide GC. Peptide 
GC contains amino acids 434-462 of GIRKl. A similar result was observed in another experiment. 
homomeric GIRK2 or GIRK4 channels [12,13,16-19] suggest 
that both GIRK2 and GIRK4 contain G|3y binding site. 
Given that the region of A.A. 318-374 of GIRKl is highly 
conserved in GIRKl^ l (Fig. 2A), we wonder whether the C-
terminal domain of GIRK2-4 would also interact with Gpy. 
Indeed, GST fusion proteins containing the C-terminal do-
mains of GIRK2 (GST-G2C), GIRK3 (GST-G3C), and 
GIRK4 (GST-G4C) all bound GPy (Fig. 2B). The GPy bind-
ing activity of GST-G2C, GST-G3C or GST-G4C is equiva-
lent to that of GST-GKCi80-374, but is less than that of GST-
GKCiso-462- The control fusion protein containing the C-ter-
minal domain of IRK1, GST-IKC, did not show significant 
binding to GPy. The greater GPy binding activity of GST-
GKCiso-462 could be accounted for by the finding that both 
the regions of A.A. 318-374 and A.A. 390-462 of the C-ter-
minal domain of GIRKl contribute to GPy binding activity. 
3.3. GPy binding site in the N-terminal domain of GIRKl^t 
The N-terminal domain of GIRKl (GKNi_86) binds GPy 
with a lower affinity as compared to the C-terminal domain 
[25]. To further isolate the region which contains the GPy 
binding activity of the N-terminal domain of GIRKl, we 
tested GST-GKNi-33 and GST-GKN34-86 for their abilities 
to bind GPy. The fusion protein GST-GKN34_86 bound GPy, 
but not as well as the full-length GST-GKN^ge did. In con-
trast, GST-GKN!_33 did not demonstrate significant binding 
to GPy (Fig. 3). As the A.A. sequence in GST-GKN34_86 of 
GIRKl is conserved in GIRKl^ l (Fig. 4A), we examined the 
interaction between GPy and the N-terminal domain of 
GIRK2 (GST-G2N), GIRK3 (GST-G3N) or GIRK4 (GST-
G4N). GST-G2N, GST-G3N and GST-G4N bound GPy as 
well as GST-GKNi_86, while the control N-terminal domain 
of IRK1 (GST-IKN) did not bind GPy (Fig. 4B). Thus, the N-
terminal domains of GIRKl^ l bound GPy. 
3.4. The N-terminal and C-terminal domains of GIRKs interact 
with each other 
Our finding of GPy binding to both the N- and C-terminal 
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GIRX1 ( 3 1 8 - 3 7 4 ) EDEVLWGHRFFPVISLEEGFFKVDYSQFHATFEVPTPPYSVKEQEEMLLMSSPLIA? 
GIRK2 ( 3 2 9 - 3 8 5 ) TSEILWGYRFTPVLTMEDGFYEVDYNSFHETYETSTPSLSAKELAELANRAEVPLSW 
GIRK3 (29 5-3 57) UDEVLWG1IRFTSVLTLEDGFYEVDYASFHETFEVPTPSCEARELAEAAAKLDAH] YW 
GIRK4 ( 3 2 4 - 3 80) DTEVLWGHRFTPVLTLEKGFYRVDYNTFHDTYETNTPSCCAKELAEMKRNGQLLQSE 
B 
Fig. 2. Binding of Gpy to C-terminal domains of GIRK2-4. (A) Sequence comparison between amino acid 318-374 of GIRK1 and homolo-
gous regions of GIRK2, 3 and 4. The number in parentheses ( ) indicates amino acids for each channel shown for comparison. Amino acids 
are shown in single-letter code. Letter in bold indicates identity or similarity of amino acids among GIRKl^l. (B) Co-precipitation of GPy 
with C-terminal domains of GIRKl^t. GST fusion protein containing C-terminal domain of GIRK1 (GST-GKCigo-462; GST-GKC180-374), 
GIRK2 (GST-G2C), GIRK3 (GST-G3C) or GIRK4 (GST-G4C) (200 nM) as indicated were incubated with Gpy (40 nM) and processed for 
co-precipitation as described in Fig. 1 and Section 2. Filter was probed with antibodies against Gp. The immunoreactivity for Gp is indicated 
by the arrow. Similar results were observed in 2 other experiments. 
domains of the GIRKs raises the possibility that the two 
domains may interact with each other to form a stronger 
binding site for G(3y- We therefore looked for interaction be-
tween GST-GKN and GST-GKC using the coprecipitation 
assay. A GST-GKC-H6 fusion protein was constructed by 
adding a hexahistidine affinity tag to the C-terminus of 
GST-GKCiso-462- A control GST-H6 was also constructed. 
By incubating a solution containing 1 uM GST-GKN and 
200 nM of either GST-GKC-H6 or GST-H6 with nickel af-
finity beads, we found that GST-GKN coprecipitated with 
Gpy binding 
+ 
B 
Gp 
Fig. 3. Gpy binding region in the N-terminal domain of GIRK1. (A) Schematic diagram of GST fusion protein constructs of the N-terminal 
domain of GIRK1 and GPy binding activities for these constructs. (+) Indicates maximal activity; (J,) denotes reduced activity; (-) indicates 
no detectable activity. (B) Localization of Gpy binding region. GST fusion proteins containing fragments of N-terminal domain of GIRK1 as 
indicated (200 nM) or the control GST alone were incubated with GPy (40 nM) and processed for coprecipitation. Nitrocellulose filter was 
probed with antibodies against Gp. The immunoreactivity for Gp is indicated by the arrow. Similar results were observed in 2 other experi-
ments. 
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GIRKl (34-86) QQQLVP--KKRQRFVDKNGRCNVQHGNIGSETSRYLSDLFTTLVDLKWRWNLFI 
GIRK2 (48-97 ) RDR TKKIQRYVRKDGKCNVHHGNV-FiETYRYLTDLFTTLVDLKWRFNLLI 
GIRK3 (18-63) RGRQRYVEKDGRCNVQQGNV-RETYRYLTDLFTTLVDLQWRLRLLF 
GIRK4 (38-92) RTRLLPEGKPRQRYMEKTGKCNVHHGNV-QETYRYLSDLFTTLVDLKWRFNLLV 
B 
«-Gp 
Fig. 4. Binding of GBy to N-terminal domains of GIRK2-4. (A) Sequence comparison between amino acids 34—86 of GIRKl and homologous 
regions of GIRK2-4. The number in parentheses ( ) indicates amino acids for each channel shown for comparison. Amino acids are shown in 
single-letter code. Letter in bold indicates identity or similarity of amino acids among GIRKl^l. (B) Co-precipitation of GBy with N-terminal 
domains of GIRKl^l. GST fusion proteins containing fragments of the N-terminal domain of GIRKl (GST-GKN), GIRK2 (GST-G2N), 
GIRK3 (GST-G3N) or GIRK4 (GST-G4N) (200 nM) as indicated were incubated with GBy (40 nM) and processed for co-precipitation. Filter 
was probed with antibodies against GB. The immunoreactivity for GB is indicated by the arrow. Similar results were observed in 3 other ex-
periments. 
GST-GKC-H6, but not with GST-H6 (Fig. 5A), indicating a 
specific protein-protein interaction between the N- and C-ter-
minal domains of GIRKl. The fusion protein GST-G4N also 
coprecipitated specifically with GST-GKC-H6 (5B), indicating 
that the C-terminal domain of GIRKl also interacts with the 
N-terminal domain of GIRK4, consistent with the previous 
reports that GIRKl and GIRK4 form heteromultimer in the 
heart [13]. 
To see if the interaction of the N-terminal domain with the 
C-terminal domain of the channel alters the binding of GPy to 
the channel fragments, we used nickel affinity beads to pre-
cipitate GST-GKC-H6, which was present at 50, 100 or 200 
nM together with GST, GST-GKN or GST-G4N and with or 
without Gpy. GST-GKN or GST-G4N coprecipitated with 
GST-GKC-H6 in a dose-dependent manner using nickel af-
finity beads (not shown). In the presence of GST, GST-GKN 
or GST-G4N, GPy coprecipitated with increasing concentra-
tions of GST-GKC-H6 in a dose-dependent manner (Fig. 6). 
However, the amount of GPy coprecipitating with 100 nM 
GST-GKC-H6 in the presence of 1 uM GST-GKN or GST-
G4N was equivalent to that with 200 nM GST-GKC-H6 in 
the presence of 1 |iM control GST. This increase in the bind-
ing of GPy to GST-GKC-H6 is more than an additive effect of 
the binding of GPy to GST-GKC-H6 and that of GPy to 
GST-GKN or GST-G4N. The N-terminal domain has a lower 
affinity for binding GPy [25]. Given that at most one tenth of 
the GST-GKN or GST-G4N coprecipitated with GST-GKC-
H6 using nickel affinity beads under the experimental condi-
G4N 
Fig. 5. Interaction between the C-terminal domain of GIRKl and the N-terminal domain of GIRKl (A) or GIRK4 (B). (A) GST-GKN (1 
U.M) was incubated with GST-GKC-H6 or the control GST-H6 (200 nM) and processed for coprecipitation by nickel affinity beads. Nitrocellu-
lose membrane was probed with antibodies against the GST-GKN. The immunoreactivity for GST-GKN is indicated by arrow. Similar results 
were obtained in 2 other experiments. (B) GST-G4N (1 uM) was incubated with GST-GKC-H6 or the control GST-H6 (200 nM) and proc-
essed for coprecipitation by nickel affinity beads. Filter was probed with antibodies against GST-G4N. The immunoreactivity for GST-G4N is 
indicated by the arrow. Similar results were observed in 2 other experiments. 
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IGST-GKC-H6] nM 
GP — 
Fig. 6. Enhanced binding of GBy to GST-GKC-H6 in the presence of GST-GKN or GST-G4N. GST-GKC-H6 (50, 100 or 200 nM) were incu-
bated with GBy (40 nM) in the presence of 1 uM GST (left panel), GST-GKN (middle panel) or GST-G4N (right panel) and processed for co-
precipitation by nickel affinity beads. Filter was probed with antibodies against GB. The immunoreactivity for GB is indicated by the arrow. A 
similar result was observed in another experiment. 
tions (see Section 2), the amount of GPy predicted to be as-
sociated with GST-GKN or GST-G4N in the precipitate 
would be negligible ( < 5 % of the observed level). Thus, the 
observed ~ 2-fold increase in Gpy binding to GST-GKC-H6 
in the presence of GST-GKN or GST-G4N indicates a syner-
gistic effect. This potentiation of GPY binding due to the in-
teraction of the N- and C-terminal domains could arise from 
the formation of a stronger GPy binding site that is contrib-
uted by both N- and C-terminal domains. Alternatively, it 
could reflect an allosteric effect between the N- and C-termi-
nal domains. Further studies are necessary to determine 
whether this synergistic effect occurs in the heteromeric chan-
nels in the heart and, if it does, whether this interaction takes 
place between the N- and C-terminal domains of the same or 
adjacent subunits. 
4. Discussion 
By studying coprecipitation of GPy with a series of fusion 
proteins containing fragments of GIRK channel subunits, we 
have found that all four mammalian GIRKs contain GPy 
binding regions and further identified regions of GIRKs 
that are important for GPy binding. Based upon the findings 
that fusion proteins GST-GKCiso-462, GST-GKC318-462, 
GST-GKCi8o-374; 390-462, GST-GKC180-374 and GST-
GKC340-462 all bound GPy and the binding activities for 
GST-GKC180-462, GST-GKC3i8-462 and GST-
GKC180-374; 390-462 were equal but greater than the activity 
for GST-GKC340-462 or GST-GKC180-374, we conclude that 
both the fragments of A.A. 318-374 and A.A. 39CM162 con-
tribute to the GPy binding activity in the C-terminal domain 
of GIRK1 (Fig. 1). The existence of GPy binding site(s) in the 
fragment of A.A. 318-374 is evident from the finding that 
both GST-GKCiso-374 and GST-GKC3i8_462 bound GPy. Ad-
dition of amino acids 390-462 to the fragment of A.A. 318— 
374 (as in GST-GKC18o-374; 390-462 or GST-GKC318-462) 
markedly enhanced the GPy binding activity of the fusion 
protein, either by providing an additional GPy binding site 
or by increasing the stability of the fusion protein. The finding 
that a peptide corresponding to A.A. 434-462 of GIRK1 par-
tially inhibited the binding of GPy to GST-GKC34o_462 sug-
gests that the fragment of A.A. 390^162 also contains binding 
site(s) for GPy. Nevertheless, as GST-GKC390-462 did not 
show detectable GPy binding, it remains possible that A.A. 
39(M-62 contributes to the Gpy binding by stabilizing the 
conformation of the fusion protein. 
With respect to the N-terminal domain, we found that ami-
no acids 34-86 of GIRK1 bound GPy, but its binding activity 
is lower compared to that of the full-length GKNi_86. The 
region of A.A. 1-33 may contribute to the maximal GPy bind-
ing activity of the N-terminal domain through providing an 
additional binding site or via stabilizing the conformation of 
the N-terminal domain. The finding that the N-terminal do-
mains of GIRK2-4 (which have significant sequence homol-
ogy to GIRK1 in the region of A.A. 34-86) bound GPy as 
well as GST-GKNi_86 is consistent with the observation that 
the region of A.A. 34-86 of GIRK1 binds GPy. Our previous 
finding of partial inhibition of the binding between GKNi_86 
and GPy by a peptide (GN) derived from A.A. 1-38 of the N-
terminal domain of GIRK1 [25], however, indicates that A.A. 
1-38 may have weak interaction with GPy. Alternatively, GN 
peptide may interact with the N-terminal domain and thereby 
interfere with the binding of GPy to GST-GKN! _86. 
We found that all 4 GIRK isoforms exhibit Gpy binding 
activity on both the N- and C-terminal domains of the chan-
nel proteins. G protein-gated inward-rectifying K+ channels 
can be comprised of identical or similar GIRK subunits. The 
heteromultimers of GIRK1 and GIRK4, and GIRK1 and 
GIRK2 correspond to some of the cardiac muscarinic G pro-
tein-gated inward-rectifying K+ channels, IKAO [13] and the 
G protein-gated K+ channel in the brain [16,20], respectively. 
While the homomultimers of GIRK2 or GIRK4 are function-
al G protein-gated K+ channels [13,16,18,19], the homomul-
timers of GIRK1 or GIRK3 do not give rise to K+ current 
[13,16,21]. Our results indicate that the inability of the homo-
multimers of GIRK1 or GIRK3 to produce K+ current is not 
due to a lack of Gpy binding domain. 
Using fusion proteins containing fragments of channel pro-
teins, we found that the GPy binding activities for the N-
terminal domain of GIRK \-A are roughly equal and that 
for the C-terminal domain of GIRK1 is greater than the bind-
ing activity for the C-terminal domain of GIRK2, 3 or 4. 
Binding of Gpy to both the N- and C-terminal domains of 
GIRK1 is important for channel activation [25,29,31]. It thus 
seems likely that binding of GPy to both the N- and C-termi-
nal domains of GIRK2, 3 or 4 is also important for channel 
activation, as the GPy binding regions of GIRK2-4 are ho-
mologous to regions of A.A. 34-86 and A.A. 318-374 of 
GIRK1. The relative contribution of each region to the over-
all binding of GPy to the full-length polypeptide or the native 
multimeric channel, however, is unknown. A previous study 
using the full-length GIRK1 and GIRK4 proteins expressed 
in Sf 9 cells reported that the GPy binding activity for GIRK4 
is slightly greater than that for GIRK1 [32]. Since we do not 
know how the individual Gpy binding region on the N- or the 
C-terminal domain folds together to form the GPy binding 
site in the full-length protein, it is difficult to compare the 
results of the two studies. Nevertheless, our investigation 
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clearly demonstrates that residues that are important for GPy 
binding are distributed on both the N- and C-termini of the 
channel. 
It is possible that the Gpy binding regions on the N- and C-
terminal cytoplasmic domains are interrelated. The two cyto-
plasmic domains interact with each other, and this interaction 
potentiates the binding of G(3y to the channel. This finding of 
synergistic action between the N- and C-terminal domains in 
the activation of channel by GPy is supported by a recent 
report by Tucker et al. [31]. In that study, they made chimera 
channels containing the transmembrane domain of the G pro-
tein-insensitive subunit Kjr4.1 and the N-terminal, the C-ter-
minal or both domains of GIRKl, and examined the role of 
these cytoplasmic domains in activation of channel by GPy. 
They found that K+ current through chimeric channels con-
taining the N- or the C-terminal domain of GIRKl was 
stimulated by Gpy by ~1 .5 - or ~2-fold, respectively; K+ 
current through chimeric channels containing both the isl-
and C-terminal domains of GIRKl, in contrast, was maxi-
mally stimulated by GPy by > 7-fold. Our results of a syner-
gistic effect between the N- and C-terminal domains for bind-
ing Gpy reinforce this physiological finding using chimeric 
channels. 
In addition to the G protein-gated inwardly rectifying K+ 
channels, GPy regulates many other effectors including phos-
pholipase C-P, phospholipase A2, type 2 adenylate cyclase, P-
adrenergic receptor kinase (PARK), and Ca2+ channel [38]. 
The Gpy binding sites for PARK [33] and phosducin [39] have 
been mapped. The consensus sequence, if any, for binding 
GPy is still elusive. Having found that synthetic peptide de-
rived from A.A. 956-982 of adenylate cyclase type 2 inhibits 
GPy activation of cyclase, phospholipase C-P, PARK and 
GIRK K+ channel, Chen et al. [36] proposed a consensus 
sequence for Gpy binding. Our result using the fusion protein 
with deletion of A.A. 375-389 does not support the idea that 
residues Asn-X-X-Glu-Arg at A.A. 378-382 are crucial for 
GIRKl binding with GPy. It is possible that other GPy bind-
ing regions of GIRKl, such as the N-terminal domain, may 
be more homologous to the region of A.A. 956-982 of adeny-
late cyclase type 2 [40]. 
Recently, the 3-dimensional crystal structures of the Py 
dimer of the G protein [41] and the ccPy trimer [42,43] have 
been solved. The P subunit consists of a seven-blade p-pro-
peller and is partially encircled by the y subunit. The interac-
tion between the a subunit and the Py dimer alters the con-
formation of the a but not of the Py subunits. Future studies 
on the structure of the Py-effector co-crystals will undoubtedly 
provide invaluable insights into the interaction between GPy 
and its effectors. 
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